<DOC>
	<DOCNO>NCT01450748</DOCNO>
	<brief_summary>Laryngopharyngeal reflux ( LPR ) , backflow gastric acid larynx hypopharynx , contribute factor hoarseness , throat clearing , throat pain , globus sensation . The therapeutic effect proton pump inhibitor ( PPIs ) controversial high placebo effect observe . Sodium Alginate effective medication indicate symptomatic treatment gastroesophageal reflux . This randomized , double-blind , placebo-controlled study aim evaluate efficacy safety profile sodium alginates oral suspension ( 50 mg/ml ) 20 ml 3 time daily treatment LPR patient Taiwan . Efficacy assessment include mean reduction total reflux symptom index ( RSI ) score 4 8 week treatment , mean reduction total reflux find score ( RFS ) 4 8 week treatment , mean change total number reflux episode measure 24-hour ambulatory combine impedance-pH monitoring 1 day 8 week treatment . Safety assessment include incidence adverse event . The study hypothesis sodium alginate superior placebo relieve LPR symptom .</brief_summary>
	<brief_title>Efficacy Safety Alginos Oral Suspension Treat Laryngopharyngeal Reflux</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled trial aim evaluate efficacy safety profile sodium alginate oral suspension ( 50mg/ml ) 20ml 3 time daily treatment patient laryngopharyngeal reflux ( LPR ) Taiwan . Patients enrol study age 12 75 year old , least one symptom consistent LPR last 4 week study , total reflux symptom index ( RSI ) &gt; 10 , total reflux find score ( RFS ) &gt; 5 , sign informed consent form . Patients exclude diagnosed erosive gastroesophageal reflux disease ( GERD ) evidence upper GI endoscopy , viral bacterial laryngitis , occupational exposure cause laryngitis , laryngeal hypopharyngeal cancer , esophageal gastric cancer , history neck radiation therapy , history esophageal gastric surgery , active pulmonary infection ( pneumonia , tuberculosis ) evidence chest X-ray , endotracheal tube intubation within 2 month enter study , take alginate preparation within 2 day ; H2-blocker , prokinetic agent antacid within 7 day ; proton pump inhibitor ( PPIs ) within 14 day screen . The primary efficacy endpoint mean reduction total RSI baseline Week 8 . The secondary efficacy endpoint mean reduction total RSI baseline Day 2 Week 4 ; mean reduction RFS baseline Week 4 Week 8 ; mean change individual component RSI baseline Day 2 , Week 4 Week 8 ; mean change individual component RFS baseline Week 4 Week 8 ; mean change total number reflux episode measure 24-hr ambulatory combine impedance-pH monitoring baseline day 2 week 8 . The safety endpoint incidence adverse event . The study hypothesis sodium alginate superior placebo treat patient LPR .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Laryngopharyngeal Reflux</mesh_term>
	<mesh_term>Alginic acid</mesh_term>
	<criteria>Patients age 1275 year old ( inclusive ) Patients least one symptom consistent LPR , include hoarseness , throat clearing , throat pain , globus sensation throat , chronic cough â‰§ 4 week enter study Patients total reflux symptom index ( RSI ) &gt; 10 ( base selfadministered 9item questionnaire voice/throat complaint ) Patients total reflux find score ( RFS ) &gt; 5 ( base laryngoscopic examination investigator ) Patients legal representative sign informed consent form Patients viral bacterial laryngitis , occupational exposure cause laryngitis Patients erosive GERD evidence upper GI endoscopy Patients laryngeal hypopharyngeal cancer , esophageal gastric cancer , , history neck radiation therapy Patients history uncontrolled hypertension moderate severe renal impairment Patients history esophageal gastric surgery Patients active pulmonary infection ( pneumonia , tuberculosis ) evidence chest Xray Patients endotracheal tube intubation within 2 month enter study Patients take alginate preparation within 2 day ; H2blocker , prokinetic agent antacid within 7 day ; proton pump inhibitor ( PPIs ) within 14 day screen Patients history allergy study drug related compound Patients history alcohol drug abuse , psychiatric disease Patients participate investigational drug trial within 4 week enter study Patients condition disease investigator considers appropriate enter study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>sodium alginate</keyword>
	<keyword>laryngopharyngeal reflux</keyword>
	<keyword>combine impedance-pH monitoring</keyword>
</DOC>